DNLI · Denali Therapeutics Inc.
$23.11
+2.04% last session
End-of-day data · updated 2026-07-28
Market cap
$4B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-9.3
Dividend yield
—
Beta
0.96
Avg volume
2M
Employees
1K
2D change
1.99%
5D change
0.64%
10D change
1.20%
30D change
-7.82%
60D change
12.02%
MTD change
-9.28%
YTD change
42.76%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — DNLI
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-23
Latest call per bank · past 12 months
Morgan Stanley
Overweight$36.00
+55.8% vs priceDeutsche Bank
Buy$35.00
+51.4% vs priceGoldman Sachs
Buy$40.00
+73.1% vs priceJP Morgan
Overweight$26.00
+12.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-23 | Morgan Stanley | Maintains | Overweight | $35.00 → $36.00 |
| 2026-07-16 | Deutsche Bank | Maintains | Buy | $31.00 → $35.00 |
| 2026-05-26 | Morgan Stanley | Maintains | Overweight | $40.00 → $35.00 |
| 2026-05-14 | Morgan Stanley | Maintains | Overweight | $42.00 → $40.00 |
| 2026-05-11 | BTIG | Reiterates | Buy | $39.00 |
| 2026-05-08 | Wedbush | Maintains | Outperform | $25.00 → $23.00 |
| 2026-04-22 | Leerink Partners | Maintains | Outperform | $40.00 → $35.00 |
| 2026-04-07 | Baird | Maintains | Outperform | $32.00 → $34.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 52 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 6.9% above the 50-day MA ($22.50).
- Price vs 200-day MA: Trading 22.2% above the 200-day MA ($19.68).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.28) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($12.75) and high ($27.21).
DNLI Price Chart
Loading chart for DNLI…
Fundamentals
About Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.